Intra-arterial thrombolysis via urokinase following reperfusion by endovascular thrombectomy for stroke does not affect survival without disability.

Endovascular thrombectomy for medium-vessel occlusion stroke shows no benefit over usual care at 90 days and is linked to increased mortality, a multicenter trial finds.

由美国心脏协会/美国卒中协会（AHA/ASA）举办的世界上首屈一指的脑血管疾病和大脑健康会议——国际卒中大会（ISC ...

Endovascular thrombectomy does not lead to better outcomes at 90 days compared with usual care or best medical treatment for patients with acute ischemic stroke due to medium vessel occlusion.

“Our results add to other recent data that support extending the therapeutic window for IV thrombolysis in acute ischemic stroke patients if endovascular thrombectomy is not available or ...

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

The global Thrombectomy Devices Market, valued at US$ 1.7 billion in 2022, is projected to advance at a compound annual ...

The following is a summary of “Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion,” published in the February ...

Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...

DelveInsight's Interventional Neuroradiology Market Insights report provides the current and forecast market analysis, individual leading interventional neuroradiology companies' market shares, ...

Medtronic also recently teamed with Tempus to assess the use of artificial intelligence to identify people eligible for ...

18, 2025 (HealthDay News) -- For patients with acute ischemic stroke (AIS) whose symptoms began 4.5 to 24 hours earlier ... Less than 3 percent of patients underwent endovascular thrombectomy (three ...